Validation of postinduction curie scores in high-risk neuroblastoma: a children's oncology group and SIOPEN group report on SIOPEN/HR-NBL1

GA Yanik, MT Parisi, A Naranjo, H Nadel… - Journal of Nuclear …, 2018 - Soc Nuclear Med
A semiquantitative 123I-metaiodobenzylguanidine (123I-MIBG) scoring method (the Curie
score, or CS) was previously examined in the Children's Oncology Group (COG) high-risk …

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group

GA Yanik, MT Parisi, BL Shulkin… - Journal of nuclear …, 2013 - Soc Nuclear Med
Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for
detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed …

Comparison of 123I‐metaiodobenzylguanidine (MIBG) and 131I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A …

A Naranjo, MT Parisi, BL Shulkin… - Pediatric blood & …, 2011 - Wiley Online Library
Abstract Background 123I‐metaiodobenzylguanidine (MIBG) scans are preferable to 131I‐
MIBG for neuroblastoma imaging as they deliver less patient radiation yet have greater …

The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma> 1 year of age on a high-risk treatment protocol: results of the …

M Schmidt, T Simon, B Hero, H Schicha… - European Journal of …, 2008 - Elsevier
AIM/PURPOSE: 123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy is well
established for staging and evaluation of response in children with high-risk neuroblastoma …

Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore …

B Decarolis, C Schneider, B Hero, T Simon… - Journal of clinical …, 2013 - ascopubs.org
Purpose Radioiodinated metaiodobenzylguanidine (123I-mIBG) scintigraphy is an
established imaging method in neuroblastoma. Semiquantitative scoring systems have been …

[HTML][HTML] Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)

N Pinto, A Naranjo, E Hibbitts, SG Kreissman… - European Journal of …, 2019 - Elsevier
Background Induction chemotherapy plays an important role in the management of patients
with high-risk neuroblastoma. Predictors of response to induction therapy are largely …

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

R Ladenstein, B Lambert, U Pötschger… - European journal of …, 2018 - Springer
Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system
in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The …

Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial

T Simon, B Hero, G Benz‐Bohm… - Pediatric blood & …, 2008 - Wiley Online Library
Background Recently, an international expert group proposed revision of the International
Neuroblastoma Staging System (INSS). Localized disease can be classified as L1 without …

Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma?

M Schmidt, T Simon, B Hero, W Eschner… - Nuklearmedizin …, 2006 - thieme-connect.com
Aim: 131 I-meta-iodobenzylguanidine (131 I-MIBG) therapy has been used in
neuroblastoma treatment for many years but its value in high intensive first line treatment …

[HTML][HTML] 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel

V Lewington, B Lambert, U Poetschger… - European Journal of …, 2017 - Springer
Purpose A robust method is required to standardise objective reporting of diagnostic 123 I-
mIBG images in neuroblastoma. Prerequisites for an appropriate system are low inter-and …